The Association between Sentinel Lymph Node Metastasis and Ki-67 Labeling Index

Background: The purpose of this study was to elucidate the association between sentinel lymph node (SLN) metastasis and Ki67 labeling index and to elucidate whether Ki-67 was useful or not for prediction of SLN metastasis in breast cancer. Methods: We identified 343 invasive breast cancer patients with sentinel lymph node biopsy (SLNB) from 2003 to 2012. The association between SLN status and clinicopathological features, molecular subtypes and Ki-67 labeling index were evaluated. Results: SLN metastasis was detected in 79 patients (23.0%). SLN metastasis was significantly associated with clinical T-stage (p = 0.0003), lymphovascular involvement (LVI) (p 0.0001). Ki-67 labeling index of primary tumor was significantly lower in SLN positive patients (p = 0.0331), and Ki-67 cut-off point of 7.5% was useful for dividing SLN positive from negative (p = 0.0197). Conclusion: Low value of Ki-67 labeling index, in addition to progression of clinical T-stage and presence of LVI, is significantly associated with SLN metastasis, and it seems to be useful to consider Ki-67 labeling index for SLN metastasis prediction.

[1]  M. Mathieu,et al.  Outcome in breast molecular subtypes according to nodal status and surgical procedures. , 2013, American journal of surgery.

[2]  A. Luini,et al.  Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. , 2013, The Lancet. Oncology.

[3]  F. Marandino,et al.  Quantitative Molecular Analysis of Sentinel Lymph Node May Be Predictive of Axillary Node Status in Breast Cancer Classified by Molecular Subtypes , 2013, PloS one.

[4]  M. Fernö,et al.  The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer , 2013, SpringerPlus.

[5]  U. Veronesi,et al.  Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: Sentinel node vs Observation after axillary UltraSouND). , 2012, Breast.

[6]  A. Luini,et al.  Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Roman Rouzier,et al.  The Molecular Subtype Classification Is a Determinant of Sentinel Node Positivity in Early Breast Carcinoma , 2011, PloS one.

[9]  A. Giuliano,et al.  Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. , 2011, JAMA.

[10]  T. Nielsen,et al.  Breast cancer subtypes and the risk of local and regional relapse. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Y. Suh,et al.  Predictors of axillary lymph node metastases (ALNM) in a Korean population with T1-2 breast carcinoma: triple negative breast cancer has a high incidence of ALNM irrespective of the tumor size. , 2010, Cancer research and treatment : official journal of Korean Cancer Association.

[12]  K. Gelmon,et al.  Ki67 in breast cancer: prognostic and predictive potential. , 2010, The Lancet. Oncology.

[13]  S. Leung,et al.  Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. , 2008, Clinical breast cancer.

[14]  Barbara L. Smith,et al.  Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Xuesong Lu,et al.  Predicting features of breast cancer with gene expression patterns , 2008, Breast Cancer Research and Treatment.

[16]  F. Meng,et al.  Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers. , 2008, Human pathology.

[17]  J. Peterse,et al.  Sentinel lymph node biopsy and non-sentinel node involvement in special type breast carcinomas with a good prognosis. , 2007, European journal of cancer.

[18]  Sung-Bae Kim,et al.  Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. , 2006, Human pathology.

[19]  G. Pruneri,et al.  Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution , 2005, Cancer.

[20]  G. Mariani,et al.  Technical issues and pathologic implications of sentinel lymph node biopsy in early‐stage breast cancer patients , 2001, Journal of surgical oncology.

[21]  M. Silverstein,et al.  Predicting Axillary Nodal Positivity in 2282 Patients with Breast Carcinoma , 2001, World Journal of Surgery.

[22]  I. Bleiweiss,et al.  Lymphatic invasion, tumor size, and age are independent predictors of axillary lymph node metastases in women with T1 breast cancers. , 1999, Annals of surgery.

[23]  S. Gapstur,et al.  Factors associated with axillary lymph node metastasis from breast carcinoma , 1999, Cancer.

[24]  D. Promish.  Prediction of axillary lymph node involvement of women with invasive breast carcinoma , 1999 .

[25]  M. Silverstein,et al.  Predictors of axillary lymph node metastases in patients with T1 breast carcinoma , 1997, Cancer.

[26]  M. Silverstein,et al.  Predicting axillary node positivity in patients with invasive carcinoma of the breast by using a combination of T category and palpability. , 1995, Journal of the American College of Surgeons.

[27]  L. Norton,et al.  Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  S Friedman,et al.  The importance of histologic grade in long-term prognosis of breast cancer: a study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Robin L. Jones,et al.  Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer , 2009, Breast Cancer Research and Treatment.

[30]  S. Huffel,et al.  Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive , 2008, Breast Cancer Research and Treatment.